Antithrombotic drug market in the Republic of Uzbekistan: dynamics, structure, and trends
https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.347
Abstract
Background. No systematic data are currently available on long-term trends in the product range, prices, and supply structure of antithrombotic drugs in the Republic of Uzbekistan, which hinders pharmaceutical supply planning.
Objective: To conduct a comprehensive analysis of the antithrombotic drug market in the Republic of Uzbekistan covering the period 2010–2024.
Materials and methods. This study presents the first multi-parametric analysis of the antithrombotic drug market in the Republic of Uzbekistan over a 15-year period. The analysis evaluated registration trends, supply volumes, price ranges, manufacturing countries, and the pharmacoeconomic characteristics of antithrombotic agents. Data were obtained from the State Register of Medicines, Medical Devices, and Medical Equipment, published by the Ministry of Health of the Republic of Uzbekistan, as well as the Drugs Audit system. Methodological approaches included product range analysis, trend analysis, price analysis, calculation of the compound annual growth rate (CAGR), and correlation analysis (Pearson correlation coefficient, p<0.05).
Results. The assortment of antithrombotic drugs expanded from 53 to 141 trade names over the period under review, with an average of approximately 50% entering active commercial circulation. Supply volumes increased 6.6-fold, peaking at 12.19 million packages (2020), followed by a decline (CAGR: −8.03%). Although imported products account for 83% of the product range, the share of domestic manufacturers has increased since 2017. The leading International Nonproprietary Names in the market include acetylsalicylic acid, enoxaparin, and clopidogrel; the market share of rivaroxaban is growing.
Conclusion. The antithrombotic drug market in the Republic of Uzbekistan has become more diversified, yet it remains import-dependent. The findings of this study can be used to inform public policy and procurement planning.
About the Authors
N.M. U. Sultanbaeva
Institute of Pharmaceutical Education and Research
Uzbekistan
Uzbekistan
Nargiza М. Sultanbayeva, PhD
46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan
Sh. Z. Umarova
Institute of Pharmaceutical Education and Research
Uzbekistan
Uzbekistan
Shakhnoz Z. Umarova, PhD, Prof.
46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan
Sh. F. Iskandarova
Institute of Pharmaceutical Education and Research
Uzbekistan
Uzbekistan
Shokhista F. Iskandarova, Dr. Pharm. Sci., Prof.
46-48 Dekhkanabad Str., Quarter 19, Yunusabad District, Tashkent 100114, Republic of Uzbekistan
References
1. Saveliev V.S., Gologorsky V.A., Kiriyenko A.I., Gelfand B.R. Prevention of venous thromboembolic complications. In: Saveliev V.S. (Ed.) Phlebology: a guide for physicians. Мoscow: Meditsina; 2001: 390–408 (in Russ.).
2. Ferro J.M. Cardioembolic stroke: an update. Lancet Neurol. 2003; 2 (3): 177–88. https://doi.org/10.1016/s1474-4422(03)00324-7.
3. Umarova Sh.Z., Sultanbaeva N.M.U. A model for optimizing pharmaceutical care for patients with coronary heart disease (CHD) to improve drug provision. In: Scientific progress as a key factor in the development of knowledge sphere: a collection of scientific papers. Kazan: SitIvent LLC; 2020: 325–31 (in Russ.).
4. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326 (5): 310–8. https://doi.org/10.1056/NEJM199201303260506.
5. Saenko V.F., Sukharev I.I., Gomolyako I.V., Vlaikov G.G. Prevention of thromboembolic complications in surgery: guidelines. Kiev; 1997 (in Russ.).
6. Caprini J.A., Tapson V.F., Hyers T.M., et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005; 42 (4): 726–33. https://doi.org/10.1016/j.jvs.2005.05.053.
7. Stevanovic G., Tucakovic G., Dotlic R., Kanjuh V. Correlation of clinical diagnoses with autopsy findings: a retrospective study of 2145 consecutive autopsies. Hum Pathol. 1986; 17 (12): 1225–30. https://doi.org/10.1016/s0046-8177(86)80564-0.
8. Hirsh J., O’Donnell M., Weitz J.I. New anticoagulants. Blood. 2005; 105 (2): 453–63. https://doi.org/10.1182/blood-2003-12-4195.
9. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008; 25 (1): 52–60. https://doi.org/10.1007/s11239-007-0108-7.
10. Turpie A.G. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2007; 29 (2): 155–65. https://doi.org/10.1093/eurheartj/ehm575.
11. Melkumyan A.L., Berkovsky A.L., Kishinets R.S., Kozlov A.A. Monitoring of the efficiency of direct anticoagulants. Russian Journal of Hematology and Transfusiology. 2013; 58 (1): 32–8 (in Russ.).
12. Kryukov A.V., Sychev D.A., Tereshchenko O.V. Pharmacogenetic aspects of new oral anticoagulants application. Rational Pharmacotherapy in Cardiology. 2017; 13 (3): 416–21 (in Russ.). https://doi.org/10.20996/1819-6446-2017-13-3-416-421.
13. Tereshin O.S. The role of direct oral anticoagulants in cancer-associated thrombosis. Review of clinical guidelines and real practice. Journal of Modern Oncology. 2024; 26 (1): 7–11 (in Russ.). https://doi.org/10.26442/18151434.2024.1.202611.
14. Global Market Insights. Anticoagulants market size, share & industry analysis report, 2023–2032. Available at: https://www.gminsights.com/industry-analysis/anticoagulants-market (accessed 12.08.2025).
15. Global anticoagulants market. Available at: https://www.databridgemarketresearch.com/ru/reports/global-anticoagulants-market?srsltid=AfmBOoqu2bqvm-px5PPP_yEWWO7CVxKkM5oXKyP_aYc2pR1el99zHSzj (accessed 12.08.2025).
16. Anticoagulants market. Available at: https://www.mordorintelligence.com/ru/industry-reports/anticoagulants-market (accessed 12.08.2025).
17. IQVIA. The global use of medicines 2023. Outlook to 2027. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2023 (accessed 12.08.2025).
18. Barnes G.D., Lucas E., Alexander G.C., Goldberger Z.D. National trends in ambulatory oral anticoagulant use. Am J Med. 2015; 128 (12): 1300–5.e.2. https://doi.org/10.1016/j.amjmed.2015.05.044.
19. World Health Organization. WHO Model List of Essential Medicines – 22nd list, 2021. Available at: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02 (accessed 12.08.2025).
20. Steffel J., Collins R., Antz M., et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23 (10): 1612–76. https://doi.org/10.1093/europace/euab065.
21. Umarova Sh.Z., Sultanbaeva N.M.U., Sharipova M.B.K. Analysis of registration of drugs in the State Register of the Republic of Uzbekistan used for diseases of the cardiovascular system. Molodoy uchenyy / Young Scientist. 2020; 8: 82–9 (in Russ.).
22. Sultanbayeva N.M.U., Umarova S.H.Z. ABC/VEN analysis of drug provision for patients with cardiovascular diseases. Pharmacoeconomics: Theory and Practice. 2020; 8 (3): 6–10 (in Russ.). https://doi.org/10.30809/phe.3.2020.1.
23. Sultanbayeva N.M.U., Umarova S.Z. Structural analysis of calcium channel blockers price dynamics in the pharmaceutical market of the Republic of Uzbekistan. Pharmacy and Pharmacology. 2024; 12 (4): 63–9 (in Russ.).
24. Umarova Sh.Z., Usmonova Z.R., Sultanbaeva N.M. Analysis of the volume of ophthalmological drugs in the pharmaceutical market of the Republic of Uzbekistan for 2024. In: Modern educational technologies in medicine and pharmaceutics: challenges and prospects. Proceedings of the International Scientific and Methodological Conference. Shymkent; 2025 (in Russ.).
25. Sultanbayeva N.M., Umarova Sh.Z., Iskandarov D.D. Meta-analysis to reveal the clinical efficacy of rivoraxaban and warfarin in the therapy of nonvalvular atrial fibrillation. Pharmacy and Pharmacology. 2022; 1 (1): 35 (in Russ.).
Review
For citations:
Sultanbaeva N.U., Umarova Sh.Z., Iskandarova Sh.F. Antithrombotic drug market in the Republic of Uzbekistan: dynamics, structure, and trends. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.347
Views:
103
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 